PLYX
Polaryx Therapeutics, Inc. Common Stock
NASDAQ: PLYX · HEALTHCARE · BIOTECHNOLOGY
$5.22
-7.28% today
Updated 2026-04-29
Market cap
$247.13M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.19
Dividend yield
—
52W range
$2 – $49
Volume
1.1M
Polaryx Therapeutics, Inc. Common Stock (PLYX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Gross margin | — | — | — |
| R&D | $2.77M | $2.81M | $6.27M |
| SG&A | $1.01M | $1.54M | $1.55M |
| Operating income | $-3.78M | $-4.35M | $-7.82M |
| Operating margin | — | — | — |
| EBITDA | $-3.78M | $-4.35M | $-7.82M |
| EBITDA margin | — | — | — |
| EBIT | — | — | — |
| Interest expense | — | — | — |
| Income tax | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% |
| Net income | $-3.78M | $-30.36M | $-8.98M |
| Net income growth (YoY) | — | -703.3% | +70.4% |
| Profit margin | — | — | — |